There was no catalyst, as there is no billion dollar market
for EDT.
If the trial is a success, this play that isn't shopping around for takers and has proven many times it isn't in the business of producing and selling their goods on their own will be taken for no more than 80 cents a share, and the hypocrite pumpers will congratulate themselves saying this once 20 cent stock (carefully choosing the price period) has turned into a 4 bagger.
That is what you should expect.
Of course, if your average is 20 cents and haven't been holding on to it for years will be rewarded.
But that's all there is to it.
And that billion dollar market is not even realistic, like all the statements coming from Spectral's management, and of course their gang of pumpers here. Sepsis affects mostly older people who suffer from multiple conditions and have been in and out of hospitals for a period of years. Doctors are not going to liberally administer PMX to everyone affected by mild to medium sepsis, knowing very well that those patients will likely be in the same sort of situation not long down the road (and families will often also choose not to unnecessarity prolong the life of their chronically ill parents).